Tivantinib (ARQ 197) is the first non-ATP-competitive c-Met inhibitor with Ki of 0.355 μM, little activity to Ron, and no inhibition to EGFR, InsR, PDGFRα or FGFR1/4. Phase 3.
生化机理
Tivantinib is an orally available, small molecule inhibitor of the c-Met receptor tyrosine kinase.